1309580-40-2
Chemical Structure
Amogammadex
Synonym(s): Adamgammadex; Aom0498
- CAS No.: 1309580-40-2
- Formula:C88H136N8O56S8
- Molecular Weight:2458.56
InChIKey: KVKTWRSAVHAYFI-RILGFENASA-N
SMILES: CC(N[C@@](C(O)=O)([H])CSC[C@@H]1[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H](O3)[C@H](O)[C@@H](O)[C@H](O[C@@H](O4)[C@H](O)[C@@H](O)[C@H](O[C@@H](O5)[C@H](O)[C@@H](O)[C@H](O[C@@H](O6)[C@H](O)[C@@H](O)[C@H]7[C@H]6CSC[C@@](C(O)=O)(NC(C)=O)[H])[C@H]5CSC[C@@](C(O)=O)(NC(C)=O)[H])[C@H]4CSC[C@]([H])(NC(C)=O)C(O)=O)[C@H]3CSC[C@@](NC(C)=O)([H])C(O)=O)[C@H](O2)CSC[C@](C(O)=O)([H])NC(C)=O)[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O)[C@@H](O7)O[C@@H]9CSC[C@](NC(C)=O)(C(O)=O)[H])O[C@@H]8CSC[C@@]([H])(C(O)=O)NC(C)=O)O1)=O
Biological Activity: Amogammadex (Adamgammadex; Aom0498) is a modified γ-cyclodextrin (HY-W040040) derivative and neuromuscular blocking agent. Amogammadex forms inactive, tight inclusion complexes with free Rocuronium (HY-17033) and Vecuronium (HY-B0118A), and reverses the neuromuscular blockade induced by them in a concentration-dependent manner. Amogammadex can be used in research related to neuromuscular blockade reversal[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Amogammadex | Amogammadex (Adamgammadex; Aom0498) is a modified γ-cyclodextrin (HY-W040040) derivative and neuromuscular blocking agent. Amogammadex forms inactive, tight inclusion complexes with free Rocuronium (HY-17033) and Vecuronium (HY-B0118A), and reverses the neuromuscular blockade induced by them in a concentration-dependent manner. Amogammadex can be used in research related to neuromuscular blockade reversal. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Qi, et al. 6-deoxy-6-thioether-amino acid cyclodextrin derivatives and preparation method thereof. WO2012068981A1. [Content Brief]
-
[2]. Zhao Y, et al. Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial. Br J Anaesth. 2025 Aug;135(2):331-339.
[Content Brief] - [3]. Stäuble CG, Blobner M. The future of neuromuscular blocking agents. Curr Opin Anaesthesiol. 2020 Aug;33(4):490-498. [Content Brief]
Keywords
